Clinical Trials Related to Merck Sharp & Dohme LLC

Related studies linked through entity extraction aliases.

Comprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresectable or Metastatic HER2 Negative Breast Cancer and a Deleterious Germline Mutation or a Homologous Recombination Deficiency (COMPRENDO

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE2

A Study of Belzutifan (MK-6482) as Monotherapy and in Combination With Lenvatinib (E7080/MK-7902) With or Without Pembrolizumab (MK-3475) in China Participants With Advanced Renal Cell Carcinoma (MK-6482-010)

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE1

Global Study of MK-2060 (Anti-Factor XI Monoclonal Antibody) in Participants With End Stage Renal Disease Receiving Hemodialysis (FXI Hemodialysis Study) (MK-2060-007)

Status: COMPLETED
Phase: PHASE2

Neoadjuvant Pembrolizumab in Cutaneous Squamous Cell Carcinoma

Status: RECRUITING
Phase: PHASE2

Epidemiology and Household Transmission of Streptococcus Pneumoniae and Respiratory Syncytial Virus

Status: NOT_YET_RECRUITING
Phase: N/A

A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180) [MK-3475A] In Advanced Solid Tumors (MK-3475A-C18)

Status: COMPLETED
Phase: PHASE1

Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11)

Status: COMPLETED
Phase: PHASE2

MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)

Status: COMPLETED
Phase: PHASE2

A Study of Pembrolizumab/Vibostolimab (MK-7684A) in Relapsed/Refractory Hematological Malignancies (MK-7684A-004, KEYVIBE-004)

Status: COMPLETED
Phase: PHASE2

A Study of Belzutifan (MK-6482) in Participants With Hepatic Impairment (MK-6482-020)

Status: COMPLETED
Phase: PHASE1

A Study of Belzutifan (MK-6482) in Participants With Renal Impairment (MK-6482-021)

Status: COMPLETED
Phase: PHASE1

A Study of SEA-CD40 Given With Other Drugs in Cancers

Status: COMPLETED
Phase: PHASE2

Study of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal Cancer

Status: RECRUITING
Phase: PHASE1

Olinvacimab With Pembrolizumab in Patients With mTNBC

Status: TERMINATED
Phase: PHASE2

PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONIN

Status: COMPLETED
Phase: PHASE2

HPV Vaccination in HIV Infected and HIV Uninfected Adolescents in Eswatini

Status: COMPLETED
Phase: PHASE4

A Study of the Safety and Tolerability in Participants With PIK3CA-related Overgrowth Spectrum or Proteus Syndrome Who Are Being Treated With Miransertib (MK-7075) in Other Studies (MK-7075-006)

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE2

HPV in Sinonasal Ca: Retrospective Analysis Association of Human Papilloma Virus (HPV) Serology and Behavioral Risk Factors

Status: COMPLETED
Phase: N/A

Immunogenicity of H. Influenzae Type b PRP-OMP Vaccines in American Indian and Alaska Native Children (the HibVax Study)

Status: COMPLETED
Phase: PHASE4

GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors

Status: RECRUITING
Phase: PHASE1/PHASE2